Jacob New
Hematology & Oncology · la Jolla, CANPI 1740800325
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 89 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 89 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$393
- Gilead$375
- AbbVie$175
- Takeda Pharmaceuticals U.S.A., Inc.$147
- Eisai Inc.$139
- Merck$131
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,488100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 5 | $393 |
| Gilead(2 entities) | 14 | $375 |
| AbbVie | 7 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $147 |
| Eisai Inc. | 6 | $139 |
| Merck | 7 | $131 |
| Amgen | 2 | $126 |
| Pharmaessentia USA Corporation | 3 | $98 |
| Pfizer | 4 | $97 |
| AstraZeneca | 3 | $71 |
| GSK | 3 | $65 |
| Deciphera Pharmaceuticals Inc. | 2 | $57 |
| Stemline Therapeutics Inc. | 2 | $55 |
| Beigene USA, Inc. | 2 | $53 |
| Seagen Inc. | 2 | $51 |
| Puma Biotechnology, Inc. | 2 | $49 |
| Array Biopharma Inc | 2 | $46 |
| Johnson & Johnson | 2 | $46 |
| Novartis | 2 | $44 |
| Bayer | 1 | $35 |
| Daiichi Sankyo Inc. | 2 | $32 |
| CSL Behring | 2 | $31 |
| Blueprint Medicines Corporation | 1 | $29 |
| ADC Therapeutics America, Inc. | 1 | $29 |
| Astellas Pharma US Inc | 1 | $24 |
| Incyte Corporation | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $20 |
| Tempus AI, Inc | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Sobi, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,488 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 14 | $143 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in la Jolla
- Alan Savenla Jolla$323K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.